诱导化疗联合放疗在早期结外NK/T细胞淋巴瘤的预后分析

doi:10.3760/cma.j.cn113030-20211017-00414

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To analyze the efficacy and prognostic factors of induced chemotherapy combined with radiotherapy in the treatment of early stage extranodal natural-killer/T cell lymphoma (ENKTCL). Methods Two hundred and eighty-seven early stage NKTCL patients were treated in Affiliated Cancer Hospital of Guizhou Medical University from October 2003 to October 2021. All patients were aDministrated with short courses of induced chemotherapy combined with radiotherapy. Clinical prognostic factors of early stage NKTCL were analyzed. The overall survival (OS) and progression-free survival (PFS) were calculated by Kaplan-Meier method, log-rank test was conducted for univariate analysis and Cox models were performed for multivariate analysis. Results The 5-year OS and PFS were 72.8% and 68.9% in all patients. According to Nomogram risk index (NRI) prognostic model, 286 patients were divided into the low risk (NRI=0), intermediate low risk (NRI=1), intermediate high risk (NRI=2), high risk (NRI=3) and very high risk (NRI≥4) groups. In these 5 groups, the 5-year OS were 95.6%,76.3%,69.5%,61.0% and 23.3%(all P<0.001), and the 5-year PFS were 93,2%, 69.8%, 64.6%, 60.2% and 23.3%(all P<0.001), respectively. In the radiotherapy with a dose of ≥50Gy and<50Gy groups, the 5-year OS were 73.8% and 65.9%(P=0.123) and the 5-year PFS were 72.8% and 45.3%(P=0.001). According to the response to induced chemotherapy of complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD), the 5-year OS were 85.4%,74.0%,61.8% and 28.5%(all P<0.001), and the 5-year PFS were 83.7%,66.8%,65.7% and 27.4%(all P<0.001), respectively. Univariate analyses showed that stage Ⅱ, ECOG≥2, primary tumor invasion, radiotherapy dose<50Gy and short-term efficacy of induced chemotherapy were poor prognostic factors for the 5-year OS and PFS (all P<0.05). Multivariate analyses demonstrated that primary tumor invasion, ECOG≥2 and stage Ⅱ were poor prognostic factors for OS (all P<0.05), and primary tumor invasion and ECOG≥2 were poor prognostic factors for PFS (all P<0.05). Conclusions Early stage NKTCL patients can obtain high efficacy after induced chemotherapy combined with radiotherapy.complete response to induced chemotherapy is associated with favorable prognosis.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Wu Tao
	Li Huan
	Liu Qiulin
	Zhang Jing
	Hu Yunfei
	Chen Mengxiang
	Huang Yunhong

Key words： Extranodal natural killer/T cell lymphoma/radiotherapy Extranodal natural killer/T cell lymphoma/chemotherapy Prognosis

Received: 17 October 2021

Cite this article:

Wu Tao,Li Huan,Liu Qiulin et al. Prognostic analysis of early stage extranodal natural-killer/T cell lymphoma treated with induced chemotherapy combined with radiotherapy[J]. Chinese Journal of Radiation Oncology, 2021, 30(12): 1250-1255.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20211017-00414 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2021/V30/I12/1250

[1] Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma:a study of 136 cases from the International Peripheral T-Cell Lymphoma Project[J]. Blood, 2009, 113(17):3931-3937. DOI:10.1182/blood-2008-10-185256.
[2] Liu QF, Wang WH, Wang SL, et al. Immunophenotypic and clinical differences between the nasal and extranasal subtypes of upper aerodigestive tract natural killer/T-cell lymphoma[J]. Int J Radiat Oncol Biol Phys, 2014, 88(4):806-813. DOI:10.1016/j.ijrobp.2013.12.005.
[3] Cao C, Feng J, Gu H, et al. Distribution of lymphoid neoplasms in Northwest China:Analysis of 3244 cases according to WHO classification in a single institution[J]. Ann Diagn Pathol, 2018, 34:60-65. DOI:10.1016/j.anndiagpath.2017.05.005.
[4] Peng RJ, Han BW, Cai QQ, et al. Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma[J]. Leukemia, 2019, 33(6):1451-1462. DOI:10.1038/s41375-018-0324-5.
[5] Jones JF, Shurin S, Abramowsky C, et al. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections[J]. N Engl J Med, 1988, 318(12):733-741. DOI:10.1056/NEJM198803243181203.
[6] Li YX, Liu QF, Fang H, et al. Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma[J]. Clin Cancer Res, 2009, 15(8):2905-2912. DOI:10.1158/1078-0432. CCR-08-2914.
[7] Jaccard A, Petit B, Girault S, et al. L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature[J]. Ann Oncol, 2009, 20(1):110-116. DOI:10.1093/annonc/mdn542.
[8] Wang L, Wang ZH, Chen XQ, et al. First-line combination of GELOX followed by radiation therapy for patients with stage Ⅰ e/ⅡE ENKTL:An updated analysis with long-term follow-up[J]. Oncol Lett, 2015, 10(2):1036-1040. DOI:10.3892/ol.2015.3327.
[9] Wu T, Yang Y, Zhu SY, et al. Risk-adapted survival benefit of IMRT in early-stage NKTCL:a multicenter study from the China Lymphoma Collaborative Group[J]. Blood Adv, 2018, 2(18):2369-2377. DOI:10.1182/bloodadvances.2018021311.
[10] Sun J, Yang Q, Lu Z, et al. Distribution of lymphoid neoplasms in China:analysis of 4,638 cases according to the World Health Organization classification[J]. Am J Clin Pathol, 2012, 138(3):429-434. DOI:10.1309/AJCP7YLTQPUSDQ5C.
[11] Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study:pathology findings and clinical outcomes[J]. J Clin Oncol, 2008, 26(25):4124-4130. DOI:10.1200/JCO.2008.16.4558.
[12] Yang Y, Zhang YJ, Zhu Y, et al. Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma, nasal-type:a multicenter study[J]. Leukemia, 2015, 29(7):1571-1577. DOI:10.1038/leu.2015.44.
[13] Li X, Cui Y, Sun Z, et al. DDGP versus SMILE in newly diagnosed advanced natural killer/T-Cell lymphoma:a randomized controlled, multicenter, open-label study in China[J]. Clin Cancer Res, 2016, 22(21):5223-5228. DOI:10.1158/1078-0432. CCR-16-0153.
[14] Qi SN, Yang Y, Song YQ, et al. First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma:a retrospective analysis from the CLCG[J]. Blood Adv, 2020, 4(13):3141-3153. DOI:10.1182/bloodadvances.2020001852.
[15] Yang Y, Zhu Y, Cao JZ, et al. Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma:analysis from a multicenter study[J]. Blood, 2015, 126(12):1424-1432;quiz 1517. DOI:10.1182/blood-2015-04-639336.
[16] Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type:a prognostic model from a retrospective multicenter study[J]. J Clin Oncol, 2006, 24(4):612-618. DOI:10.1200/JCO.2005.04.1384.
[17] Suzuki R, Suzumiya J, Yamaguchi M, et al. Prognostic factors for mature natural killer (NK) cell neoplasms:aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type[J]. Ann Oncol, 2010, 21(5):1032-1040. DOI:10.1093/annonc/mdp418.
[18] Chen SY, Yang Y, Qi SN, et al. Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era:indication for prognostication and clinical decision-making[J]. Leukemia, 2021, 35(1):130-142. DOI:10.1038/s41375-020-0791-3.
[19] Qi SN, Yang Y, Zhang YJ, et al. Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era:a China lymphoma collaborative group study[J]. Am J Hematol, 2020, 95(9):1047-1056. DOI:10.1002/ajh.25878.
[20] Hong H, Li Y, Lim ST, et al. A proposal for a new staging system for extranodal natural killer T-cell lymphoma:a multicenter study from China and Asia lymphoma study group[J]. Leukemia, 2020, 34(8):2243-2248. DOI:10.1038/s41375-020-0740-1.
[21] Yang Y, Cao JZ, Lan SM, et al. Association of improved locoregional control with prolonged survival in early-stage extranodal nasal-type natural killer/T-Cell lymphoma[J]. JAMA Oncol, 2017, 3(1):83-91. DOI:10.1001/jamaoncol.2016.5094.
[22] Wang B, Li XQ, Ma X, et al. Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type[J]. Am J Hematol, 2008, 83(10):795-799. DOI:10.1002/ajh.21256.
[23] Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells[J]. Cancer, 1995, 76(11):2351-2356. DOI:10.1002/1097-0142(19951201)76:11<2351::aid-cncr2820761125>3.0.co;2-1.
[24] Drénou B, Lamy T, Amiot L, et al. CD3-CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance[J]. Blood, 1997, 89(8):2966-2974.
[25] Wang L, Wang ZH, Chen XQ, et al. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage Ⅰ e/ⅡE extranodal natural killer/T-cell lymphoma[J]. Cancer, 2013, 119(2):348-355. DOI:10.1002/cncr.27752.
[26] Yamaguchi M, Suzuki R, Kwong YL, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia[J]. Cancer Sci, 2008, 99(5):1016-1020. DOI:10.1111/j.1349-7006.2008.00768.x.